NEWS
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time.
Key features of HFX AdaptivAI include:
Continuous therapy optimization
Bipole Interlacing™ for customized programs
Smart Power technology for reduced charging frequency
Real-time quality of life metrics and device data collection
Advanced proactive remote monitoring for physicians
Nevro expects a full market release in the U.S. in Q4 2024, positioning itself as a leader in data-driven pain management solutions.
Key features of HFX AdaptivAI include:
Continuous therapy optimization
Bipole Interlacing™ for customized programs
Smart Power technology for reduced charging frequency
Real-time quality of life metrics and device data collection
Advanced proactive remote monitoring for physicians
Nevro expects a full market release in the U.S. in Q4 2024, positioning itself as a leader in data-driven pain management solutions.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2624Followers
107Following
28KVisitors
Follow